MENU
+Compare
SLRX
Stock ticker: NASDAQ
AS OF
Jun 5, 04:57 PM (EDT)
Price
$0.76
Change
-$0.02 (-2.56%)
Capitalization
1.6M

SLRX Salarius Pharmaceuticals Inc. Forecast, Technical & Fundamental Analysis

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs... Show more

SLRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for SLRX with price predictions
Jun 04, 2025

Momentum Indicator for SLRX turns negative, indicating new downward trend

SLRX saw its Momentum Indicator move below the 0 level on May 29, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In of the 89 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for SLRX moved out of overbought territory on May 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for SLRX turned negative on June 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SLRX broke above its upper Bollinger Band on May 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 77 cases where SLRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

SLRX moved above its 50-day moving average on May 14, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SLRX crossed bullishly above the 50-day moving average on May 19, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SLRX advanced for three days, in of 223 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 55 cases where SLRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SLRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.907) is normal, around the industry mean (16.306). P/E Ratio (0.000) is within average values for comparable stocks, (59.921). SLRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (265.014).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SLRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company, which operates through the Consumer Operations and Drug Development segments.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2450 Holcombe Boulevard
Phone
+1 832 834-9144
Employees
2
Web
https://www.salariuspharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLBT16.840.18
+1.08%
Cellebrite DI Ltd
CHMI2.970.02
+0.68%
CHERRY HILL MORTGAGE INVESTMENT Corp
UFCS28.130.04
+0.14%
United Fire Group
STKH2.44N/A
+0.01%
Steakholder Foods Ltd
WEX136.44-1.84
-1.33%
WEX

SLRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SLRX has been closely correlated with MBIO. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if SLRX jumps, then MBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLRX
1D Price
Change %
SLRX100%
-2.51%
MBIO - SLRX
71%
Closely correlated
N/A
AZTR - SLRX
40%
Loosely correlated
+3.02%
PHIO - SLRX
36%
Loosely correlated
+0.48%
NRSN - SLRX
32%
Poorly correlated
-2.30%
KNSA - SLRX
29%
Poorly correlated
-0.79%
More

Groups containing SLRX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLRX
1D Price
Change %
SLRX100%
-2.51%
SLRX
(2 stocks)
20%
Poorly correlated
-3.28%